Christine Pich-Bavastro

Dr. Christine Pich-Bavastro

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LYLaura Yerly
Laura Yerly
CPChristine Pich-Bavastro
Christine Pich-Bavastro
JDJeremy Di Domizio
Jeremy Di Domizio
TWTania Wyss
Tania Wyss
STStéphanie Tissot-Renaud
Stéphanie Tissot-Renaud
FKFrançois Kuonen
François Kuonen
Tumors invade the surrounding tissues to progress, but the heterogeneity of cell types at the tumor-stroma interface and the complexity of their potential interactions hampered mechanistic insight required for efficient therapeutic targeting. Here, combining single-cell and spatial transcriptomics on human basal cell carcinomas, we define the cellular contributors of tumor progression. In the invasive niche, tumor cells exhibit a collective migration phenotype, characterized by the expression of cell-cell junction complexes. In physical proximity, we identify cancer-associated fibroblasts with extracellular matrix-remodeling features. Tumor cells strongly express the cytokine Activin A, and increased Activin A-induced gene signature is found in adjacent cancer-associated fibroblast subpopulations. Altogether, our data identify the cell populations and their transcriptional reprogramming contributing to the spatial organization of the basal cell carcinoma invasive niche. They also demonstrate the power of integrated spatial and single-cell multi-omics to decipher cancer-specific invasive properties and develop targeted therapies.

15 December 2015 in British Journal of Cancer
Verified
Journal Article
Open access
CPChristine Pich-Bavastro
Christine Pich-Bavastro
GSGuillaume Sarrabayrouse
Guillaume Sarrabayrouse
ITIotefa Teiti
Iotefa Teiti
BMBernard Mariamé
Bernard Mariamé
PRPhilippe Rochaix
Philippe Rochaix
ATAnne-Françoise Tilkin-Mariamé
Anne-Françoise Tilkin-Mariamé
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

20 May 2025 in Nature Cancer
Verified
Journal Article
Open access
HHHelen Carrasco Hope
Helen Carrasco Hope
JSJana de Sostoa
Jana de Sostoa
PGPierpaolo Ginefra
Pierpaolo Ginefra
MAMassimo Andreatta
Massimo Andreatta
YCYi-Hsuan Chiang
Yi-Hsuan Chiang
NVNicola Vannini
Nicola Vannini
Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments. However, different hurdles are limiting its application and efficacy. In this context, how aging influences CAR-T cell outcomes is largely unknown. Here we show that CAR-T cells generated from aged female mice present a mitochondrial dysfunction derived from nicotinamide adenine dinucleotide (NAD) depletion that leads to poor stem-like properties and limited functionality in vivo. Moreover, human data analysis revealed that both age and NAD metabolism determine the responsiveness to CAR-T cell therapy. Targeting NAD pathways, we were able to recover the mitochondrial fitness and functionality of CAR-T cells derived from older adults. Altogether, our study demonstrates that aging is a limiting factor to successful CAR-T cell responses. Repairing metabolic and functional obstacles derived from age, such as NAD decline, is a promising strategy to improve current and future CAR-T cell therapies.

1 January 2013 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CPChristine Pich-Bavastro
Christine Pich-Bavastro
ITIotefa Teiti
Iotefa Teiti
PRPhilippe Rochaix
Philippe Rochaix
BMBernard Mariamé
Bernard Mariamé
BCBettina Couderc
Bettina Couderc
ATAnne-Françoise Tilkin-Mariamé
Anne-Françoise Tilkin-Mariamé
Survival of melanoma patients after metastases detection remains short. Several clinical trials have shown moderate efficiency in improving patient survival, and the search for pharmacological agents to enhance the immune response and reduce melanoma metastases is still necessary. Statins block the mevalonate pathway, which leads to decreases in GTPase isoprenylation and activity, particularly those of the Ras superfamily. They are widely used as hypocholesterolemic agents in cardiovascular diseases and several studies have shown that they also have protective effects against cancers. Furthermore, we have previously demonstrated that treatment of melanoma cells with inhibitors of the mevalonate pathway, such as statins, favor the development of specific adaptive immune responses against these tumors. In the present study, we tested statin impact on the innate immune response against human metastatic melanoma cells. Our data shows that treatment of two human melanoma cell lines with statins induced a weak but significant increase of MHC class I Chain-related protein A (MICA) membrane expression. Peroxisome Proliferator-Activated Receptor gamma is involved in this statin-induced MICA overexpression, which is independent of Ras and Rho GTPase signaling pathways. Interestingly, this MICA overexpression makes melanoma cells more sensitive to in vitro lysis by NK cells. The impact of statin treatment on in vivo development of melanoma tumors and metastases was investigated in nude mice, because murine NK cells, which express NKG2D receptors, are able to recognize and kill human tumor cells expressing MICA. The results demonstrated that both local tumor growth and pulmonary metastases were strongly inhibited in nude mice injected with statin-treated melanoma cells. These results suggest that statins could be effective in melanoma immunotherapy treatments.

1 June 2016 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
GDGwendoline Degueurce
Gwendoline Degueurce
IDIlenia D'ERrico
Ilenia D'ERrico
CPChristine Pich-Bavastro
Christine Pich-Bavastro
MIMark Ibberson
Mark Ibberson
FSFrédéric Schütz
Frédéric Schütz
LMLiliane Michalik
Liliane Michalik
Although excessive exposure to UV is widely recognized as a major factor leading to skin perturbations and cancer, the complex mechanisms underlying inflammatory skin disorders resulting from UV exposure remain incompletely characterized. The nuclear hormone receptor PPARβ/δ is known to control mouse cutaneous repair and UV‐induced skin cancer development. Here, we describe a novel PPARβ/δ‐dependent molecular cascade involving TGFβ1 and miR‐21‐3p, which is activated in the epidermis in response to UV exposure. We establish that the passenger miRNA miR‐21‐3p, that we identify as a novel UV‐induced miRNA in the epidermis, plays a pro‐inflammatory function in keratinocytes and that its high level of expression in human skin is associated with psoriasis and squamous cell carcinomas. Finally, we provide evidence that inhibition of miR‐21‐3p reduces UV‐induced cutaneous inflammation in ex vivo human skin biopsies, thereby underlining the clinical relevance of miRNA‐based topical therapies for cutaneous disorders. Synopsis The skin response to UV as well as psoriasis or squamous cell carcinoma are complex pathophysiological situations. The microRNA miR‐21‐3p is shown to be a novel target of PPARβ/δ and TGFβ that controls inflammation in mouse and human epidermis. miR‐21‐3p is induced by UV irradiation in mouse and human epidermis. PPARβ/δ and TGFβ activation is required for UV‐induced miR‐21‐3p upregulation in the epidermis. Elevated miR‐21‐3p level correlates with psoriasis and squamous cell carcinoma in human skin. Inhibition of miR‐21‐3p reduces UV‐induced inflammation in human skin ex vivo.

16 June 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CPChristine Pich-Bavastro
Christine Pich-Bavastro
LYLaura Yerly
Laura Yerly
JDJeremy Di Domizio
Jeremy Di Domizio
STStéphanie Tissot-Renaud
Stéphanie Tissot-Renaud
MGMichel Gilliet
Michel Gilliet
FKFrançois Kuonen
François Kuonen
Purpose: Cemiplimab is approved for the treatment of locally advanced basal cell carcinomas (BCC), although with mitigated results. We sought to interrogate the cellular and molecular transcriptional reprogramming underlying BCC resistance to immunotherapy. Experimental Design: Here, we combined spatial and single-cell transcriptomics to deconvolute the spatial heterogeneity of the tumor microenvironment in regard with response to immunotherapy, in a cohort of both naïve and resistant BCCs. Results: We identified subsets of intermingled cancer-associated fibroblasts (CAF) and macrophages contributing the most to CD8 T-cell exclusion and immunosuppression. Within this spatially resolved peritumoral immunosuppressive niche, CAFs and adjacent macrophages were found to display Activin A–mediated transcriptional reprogramming towards extracellular matrix remodeling, suggesting active participation to CD8 T-cell exclusion. In independent datasets of human skin cancers, Activin A–conditioned CAFs and macrophages were associated with resistance to immune checkpoint inhibitors (ICI). Conclusions: Altogether, our data identify the cellular and molecular plasticity of tumor microenvironment (TME) and the pivotal role of Activin A in polarizing the TME towards immune suppression and ICI resistance.